Supernus Pharmaceuticals IncSUPN
Price$42.18Intrinsic value$35.2117% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $830.4M+25.5% YoYTTM through 30 Jun 2026
Net Income -$109.9M-248.8% YoYTTM through 30 Jun 2026
Free Cash Flow $18.8MTTM through 30 Jun 2026

Margins

Current
Gross Margin88.7%
EBITDA Margin-3.5%
Operating Margin-4.0%
Net Margin-13.2%

Returns

-10.7%ROE
-7.7%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio2.08x
Net Debt-$384.2Mnet cash position
Cash & Equivalents$180M

Quality Metrics

Altman Z-Score4.90
Piotroski F-Score4 / 9
FCF Margin2.3%
Rule of 408.9
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $719M
Diluted EPS-$1.92TTM
'19'20'21'22'23'24'25
FY2025: $-0.68

Dividend

No dividend

Capital Allocation

R&D Spend$126.1M
Capex Intensity0.1%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.